RxDoctor Payments DataLook up a doctor →

Gladys Dolor, APRN

Nurse Practitioner · Carson City, NVNPI 1285207043

Payments from drug & device makers

$13,427in general payments, 2019–2025

Across 518 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$1K
  • Johnson & Johnson$989
  • Merck$706
  • Astellas Pharma US Inc$692
  • Incyte Corporation$684
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.58$1,600
AstraZeneca(2 entities)50$1,494
Johnson & Johnson34$989
Merck30$706
Astellas Pharma US Inc29$692
Incyte Corporation24$684
Amgen16$485
Novartis23$449
Daiichi Sankyo Inc.27$429
Gilead(2 entities)11$372
Genentech USA, Inc.12$342
Bristol Myers Squibb10$296
Pfizer13$281
Eisai Inc.13$278
Regeneron Healthcare Solutions, Inc.8$254
AbbVie15$252
Ipsen Biopharmaceuticals, Inc10$224
GSK9$192
Jazz Pharmaceuticals Inc.2$165
Karyopharm Therapeutics Inc.3$164
Array Biopharma Inc6$161
Sanofi7$155
Exelixis Inc.4$153
Springworks Therapeutics, Inc.6$152
Sobi, Inc5$143
Tersera Therapeutics LLC6$134
Apellis Pharmaceuticals, Inc.2$125
EMD Serono, Inc.6$125
Servier Pharmaceuticals LLC7$125
Takeda Pharmaceuticals U.S.A., Inc.5$119
Beigene USA, Inc.4$113
AVEO Pharmaceuticals, Inc.3$102
Seagen Inc.1$100
Lilly USA, LLC4$85
Stemline Therapeutics Inc.3$83
Sanofi-aventis U.S. LLC1$79
Deciphera Pharmaceuticals Inc.3$75
Kyowa Kirin, Inc.3$75
Boehringer Ingelheim3$73
Pharmacyclics LLC, An Abbvie Company3$65
Accord Healthcare, Inc.3$62
Mirati Therapeutics, Inc.2$59
Genmab U.S., Inc.2$53
Pharmaessentia USA Corporation2$52
Organon3$48
Bayer2$48
Novocure Inc.2$47
Rigel Pharmaceuticals, Inc.2$41
Azurity Pharmaceuticals, Inc.2$39
Blueprint Medicines Corporation2$38
ADC Therapeutics America, Inc.1$35
Coherus Oncology, Inc.1$27
Pharmacosmos Therapeutics Inc.1$24
Sumitomo Pharma America, Inc.1$22
Tactile Systems Technology Inc1$22
Octapharma USA, Inc.1$22
Adaptive Biotechnologies Corporation1$22
Biocon Biologics Inc1$22
Blue Earth Diagnostics1$21
Agios Pharmaceuticals, Inc.1$20

How this compares

$13,427 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada →

Medicare billing

Part B allowed, 2024
$83,454
Medicare patients
394
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Carson City

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →